IN2014DN06737A - - Google Patents

Info

Publication number
IN2014DN06737A
IN2014DN06737A IN6737DEN2014A IN2014DN06737A IN 2014DN06737 A IN2014DN06737 A IN 2014DN06737A IN 6737DEN2014 A IN6737DEN2014 A IN 6737DEN2014A IN 2014DN06737 A IN2014DN06737 A IN 2014DN06737A
Authority
IN
India
Prior art keywords
composition
formulated
present
administration
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Sadasivan Vidyasagar
Paul Okunieff
Lurong Zhang
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of IN2014DN06737A publication Critical patent/IN2014DN06737A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/20Elemental chlorine; Inorganic compounds releasing chlorine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IN6737DEN2014 2012-02-08 2013-02-08 IN2014DN06737A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596480P 2012-02-08 2012-02-08
PCT/US2013/025294 WO2013119917A1 (en) 2012-02-08 2013-02-08 Materials and methods for treating diarrhea

Publications (1)

Publication Number Publication Date
IN2014DN06737A true IN2014DN06737A (ja) 2015-05-22

Family

ID=48948047

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6737DEN2014 IN2014DN06737A (ja) 2012-02-08 2013-02-08

Country Status (15)

Country Link
US (3) US20140377374A1 (ja)
EP (1) EP2812007B1 (ja)
JP (1) JP6084238B2 (ja)
KR (2) KR102262179B1 (ja)
CN (1) CN104093410B (ja)
AP (1) AP3941A (ja)
AU (1) AU2013216871B2 (ja)
BR (1) BR112014019350B1 (ja)
CA (1) CA2863388C (ja)
EA (1) EA034014B1 (ja)
ES (1) ES2862392T3 (ja)
HK (1) HK1204290A1 (ja)
IN (1) IN2014DN06737A (ja)
MX (1) MX368543B (ja)
WO (1) WO2013119917A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173079B1 (en) 2010-09-24 2020-04-22 University of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
WO2014164736A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
EP3459540A1 (en) * 2014-11-24 2019-03-27 Entrinsic Health Solutions, Inc. Amino acid compositions for the treatment of symptoms of disease
EP3522882A4 (en) 2016-10-04 2020-06-24 The University of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND USES THEREOF
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA
WO2021247652A1 (en) * 2020-06-02 2021-12-09 University Of Florida Research Foundation, Inc. Formulations and methods for treating diarrhea
KR20230047371A (ko) * 2020-07-02 2023-04-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 수화를 촉진하기 위한 제형 및 이의 사용 방법
MX2023014015A (es) * 2021-05-28 2024-02-08 Coca Cola Co Formulación aminoácidica hidratante y método de uso.
CN115531363B (zh) * 2021-06-30 2024-03-29 中国科学技术大学 预防、抑制或治疗轮状病毒感染的药物组合物及其用途
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
JP3301646B2 (ja) * 1993-03-19 2002-07-15 シスメックス株式会社 幼若細胞測定用試薬
ATE287703T1 (de) * 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
JP4255656B2 (ja) * 2001-09-17 2009-04-15 株式会社メニコン 眼科用液剤及びコンタクトレンズ用液剤
US20030143293A1 (en) * 2002-01-31 2003-07-31 Sergei Shushunov Compositions and methods for treating diarrhea
JP2004123642A (ja) 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd 電解質組成物
DK175877B1 (da) * 2002-11-11 2005-05-09 Pharmalett As Præparater til anvendelse som terapeutisk middel
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
JP4811576B2 (ja) 2005-03-31 2011-11-09 味の素株式会社 水分電解質補給飲料
JP4512013B2 (ja) * 2005-09-07 2010-07-28 和光堂株式会社 液体飲料組成物及びその製造方法
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung
EP3173079B1 (en) 2010-09-24 2020-04-22 University of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
WO2014164736A1 (en) * 2013-03-11 2014-10-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications

Also Published As

Publication number Publication date
EA034014B1 (ru) 2019-12-19
AP2014007916A0 (en) 2014-09-30
MX368543B (es) 2019-10-07
AP3941A (en) 2016-12-16
AU2013216871B2 (en) 2017-08-17
CN104093410A (zh) 2014-10-08
KR20200105525A (ko) 2020-09-07
EP2812007A1 (en) 2014-12-17
ES2862392T3 (es) 2021-10-07
WO2013119917A1 (en) 2013-08-15
CA2863388C (en) 2020-11-17
MX2014009557A (es) 2014-11-10
JP2015506981A (ja) 2015-03-05
BR112014019350B1 (pt) 2020-09-24
BR112014019350A8 (pt) 2017-07-11
AU2013216871A1 (en) 2014-09-11
JP6084238B2 (ja) 2017-02-22
EP2812007B1 (en) 2020-12-30
US20210299076A1 (en) 2021-09-30
EP2812007A4 (en) 2015-09-09
CN104093410B (zh) 2018-04-27
KR102262179B1 (ko) 2021-06-07
EA201400827A1 (ru) 2014-12-30
US20150297636A1 (en) 2015-10-22
KR20140120941A (ko) 2014-10-14
BR112014019350A2 (ja) 2017-06-20
CA2863388A1 (en) 2013-08-15
HK1204290A1 (en) 2015-11-13
US20140377374A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
IN2014DN06737A (ja)
CA2956871C (en) Compounds active towards bromodomains
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2019014045A (es) Composiciones y metodos.
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
EP3904502A3 (en) Compositions and methods
IN2015DN01156A (ja)
MX2013004061A (es) Analogos de ciclosporina.
WO2014145958A3 (en) Network-based microbial compositions and methods
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
GB201106750D0 (en) Novel compounds
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
EA030970B8 (ru) Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2011007930A (es) Conjugados de insulina cristalina.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
IN2012DN02735A (ja)
IN2012DN02730A (ja)
IN2012DN00754A (ja)
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
GB201106743D0 (en) Novel compounds
MY162146A (en) Pharmaceutical composition
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
WO2015161243A3 (en) Beta-lactamases with improved properties for therapy
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.